Sulforaphane prevents diabetes‐induced hepatic ferroptosis by activating Nrf2 signaling axis
Open Access
- 1 February 2024
- journal article
- research article
- Published by Wiley in BioFactors
- Vol. 50 (4) , 810-827
Abstract
Recently, we characterized the ferroptotic phenotype in the liver of diabetic mice and revealed nuclear factor (erythroid‐derived‐2)‐related factor 2 (Nrf2) inactivation as an integral part of hepatic injury. Here, we aim to investigate whether sulforaphane, an Nrf2 activator and antioxidant, prevents diabetes‐induced hepatic ferroptosis and the mechanisms involved. Male C57BL/6 mice were divided into four groups: control (vehicle‐treated), diabetic (streptozotocin‐induced; 40 mg/kg, from Days 1 to 5), diabetic sulforaphane‐treated (2.5 mg/kg from Days 1 to 42) and non‐diabetic sulforaphane‐treated group (2.5 mg/kg from Days 1 to 42). Results showed that diabetes‐induced inactivation of Nrf2 and decreased expression of its downstream antiferroptotic molecules critical for antioxidative defense (catalase, superoxide dismutases, thioredoxin reductase), iron metabolism (ferritin heavy chain (FTH1), ferroportin 1), glutathione (GSH) synthesis (cystine‐glutamate antiporter system, cystathionase, glutamate‐cysteine ligase catalitic subunit, glutamate‐cysteine ligase modifier subunit, glutathione synthetase), and GSH recycling ‐ glutathione reductase (GR) were reversed/increased by sulforaphane treatment. In addition, we found that the ferroptotic phenotype in diabetic liver is associated with increased ferritinophagy and decreased FTH1 immunopositivity. The antiferroptotic effect of sulforaphane was further evidenced through the increased level of GSH, decreased accumulation of labile iron and lipid peroxides (4‐hydroxy‐2‐nonenal, lipofuscin), decreased ferritinophagy and liver damage (decreased fibrosis, alanine aminotransferase, and aspartate aminotransferase). Finally, diabetes‐induced increase in serum glucose and triglyceride level was significantly reduced by sulforaphane. Regardless of the fact that this study is limited by the use of one model of experimentally induced diabetes, the results obtained demonstrate for the first time that sulforaphane prevents diabetes‐induced hepatic ferroptosis in vivo through the activation of Nrf2 signaling pathways. This nominates sulforaphane as a promising phytopharmaceutical for the prevention/alleviation of ferroptosis in diabetes‐related pathologies.Keywords
Funding Information
- Science Fund of the Republic of Serbia (6525651)
This publication has 76 references indexed in Scilit:
- Glutathione synthesisBiochimica et Biophysica Acta (BBA) - General Subjects, 2013
- Mechanisms of Diabetic ComplicationsPhysiological Reviews, 2013
- Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell DeathCell, 2012
- Blackberry Extract Attenuates Oxidative Stress through Up-regulation of Nrf2-Dependent Antioxidant Enzymes in Carbon Tetrachloride-Treated RatsJournal of Agricultural and Food Chemistry, 2011
- Cell Death and FibrogenesisSeminars in Liver Disease, 2010
- Sulforaphane protects liver injury induced by intestinal ischemia reperfusion through Nrf2-ARE pathwayWorld Journal of Gastroenterology, 2010
- Sulforaphane as an inducer of glutathione prevents oxidative stress‐induced cell death in a dopaminergic‐like neuroblastoma cell lineJournal of Neurochemistry, 2009
- Dietary Hesperidin Exerts Hypoglycemic and Hypolipidemic Effects in Streptozotocin-Induced Marginal Type 1 Diabetic RatsJournal of Clinical Biochemistry and Nutrition, 2009
- Synergy between sulforaphane and selenium in the induction of thioredoxin reductase 1 requires both transcriptional and translational modulationCarcinogenesis, 2003
- Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridineAnalytical Biochemistry, 1980